CClinicalTrials.gg
AvailableNCT04143295DITPAUpdated Dec 11, 2025

Rescue of Infants With MCT8 Deficiency

An expanded access record providing Diiodothyropropionic acid (DITPA) in Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, sponsored by Roy E. Weiss, M.D.. Available at 1 site in United States. Open to male participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Roy E. Weiss, M.D. · Expanded access

Study type
Expanded access
Access type
Individual patients · Treatment IND/protocol
Ages
Up to 18 Years
Sex
Male
01

Study summary

Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.

02

Conditions studied

  • Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency
03

In context

Lead sponsor

This is the only study on the registry with Roy E. Weiss, M.D. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Genetic Confirmation: Male fetus or fetuses (including monozygotic twin pregnancies) must have a confirmed MCT8 gene mutation.
  • Family History: A previously born child or children with a severe, typical phenotype and an MCT8 gene mutation identical to that of the fetus.
  • Alternatively, the mother or a sister must have a relative with a known MCT8 defect.
  • Parental Decision: Parental refusal to terminate the pregnancy despite the diagnosis of MCT8 deficiency.
  • Compliance and Availability: Willingness of the parents to comply with all study procedures and ensure availability for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy-Related Factors: Dizygotic (non-identical) twin pregnancy (unless only one fetus is confirmed with the MCT8 mutation, and the unaffected fetus will not be treated).

Parental decision to terminate the pregnancy.

  • Maternal Medical Conditions: Hyperthyroidism requiring treatment. Significant liver or kidney insufficiency. Congestive heart failure. Hyperemesis gravidarum unresponsive to treatment.
  • Significant cardiac conditions, including:
  • Atrial fibrillation or other arrhythmias.
  • Unstable angina.
  • Coronary heart disease.
  • Medications:

Current use of sympathomimetic therapy. Anticoagulant therapy. Use of Cytochrome P450 2C9 (CYP2C9) inhibitors with a narrow therapeutic index.

  • Other Factors: Major illness or recent major surgery within four weeks of baseline visit 1, unrelated to MCT8 deficiency.
05

Access details

Study type
Expanded access
Access type
Individual patients · Treatment IND/protocol

Available treatment

  • DrugDiiodothyropropionic acid (DITPA)

    Drug Administration

06

Where to request access

1 of 1 sites recruiting
  • University of Miami, Miller School of Medicine
    Miami, Florida 33136, United States
    • Roy E Weiss, M.D. · Contact · rweiss@med.miami.edu · (305) 243-1944
    • Roy E Weiss, M.D. · Principal investigator
    Available
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT04143295
Lead sponsor
Roy E. Weiss, M.D.
Responsible party
Roy E. Weiss, M.D. (Principal Investigator, University of Miami) — Sponsor-investigator
First posted
Oct 29, 2019
Last update
Dec 11, 2025

Study contacts

Roy E Weiss, M.D.
Contact
rweiss@med.miami.edu
(305) 243-1944
Roy E Weiss, M.D.
principal investigator · University of Miami
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion